Literature DB >> 18430665

Aortic valve replacement in a patient with morquio syndrome.

Francesco Nicolini1, Domenico Corradi, Silvia Bosio, Tiziano Gherli.   

Abstract

Cardiac involvement in Morquio syndrome, mucopolysaccharidosis IV, is characterized by aortic and mitral valve thickening and infiltration of the coronary arteries. There are few reports concerning surgical interventions in patients with mucopolysaccharidoses. We report a case of a patient affected by Morquio syndrome who underwent aortic valve replacement surgery for severe aortic valve stenosis, with an uneventful postoperative course. Cardiac surgery appears safe and feasible in these patients and improves the quality of life, even if the future prognosis related to the underlying disorder should be considered.

Entities:  

Mesh:

Year:  2008        PMID: 18430665     DOI: 10.1532/HSF98.20071197

Source DB:  PubMed          Journal:  Heart Surg Forum        ISSN: 1098-3511            Impact factor:   0.676


  12 in total

1.  Anaesthetic considerations of adults with Morquio's syndrome - a case report.

Authors:  Anne Marie McLaughlin; Muhammad Farooq; Maria B Donnelly; Kieran Foley
Journal:  BMC Anesthesiol       Date:  2010-02-26       Impact factor: 2.217

Review 2.  Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA.

Authors:  Hira Peracha; Kazuki Sawamoto; Lauren Averill; Heidi Kecskemethy; Mary Theroux; Mihir Thacker; Kyoko Nagao; Christian Pizarro; William Mackenzie; Hironori Kobayashi; Seiji Yamaguchi; Yasuyuki Suzuki; Kenji Orii; Tadao Orii; Toshiyuki Fukao; Shunji Tomatsu
Journal:  Mol Genet Metab       Date:  2018-05-15       Impact factor: 4.797

Review 3.  Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA.

Authors:  C J Hendriksz; P Harmatz; M Beck; S Jones; T Wood; R Lachman; C G Gravance; T Orii; S Tomatsu
Journal:  Mol Genet Metab       Date:  2013-04-10       Impact factor: 4.797

4.  Current and emerging management options for patients with Morquio A syndrome.

Authors:  Mohamed F Algahim; G Hossein Almassi
Journal:  Ther Clin Risk Manag       Date:  2013-02-11       Impact factor: 2.423

Review 5.  Clinical overview and treatment options for non-skeletal manifestations of mucopolysaccharidosis type IVA.

Authors:  Christian J Hendriksz; Maisoon Al-Jawad; Kenneth I Berger; Sara M Hawley; Rebecca Lawrence; Ciarán Mc Ardle; C Gail Summers; Elizabeth Wright; Elizabeth Braunlin
Journal:  J Inherit Metab Dis       Date:  2012-02-23       Impact factor: 4.982

Review 6.  Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management.

Authors:  Elizabeth A Braunlin; Paul R Harmatz; Maurizio Scarpa; Beatriz Furlanetto; Christoph Kampmann; James P Loehr; Katherine P Ponder; William C Roberts; Howard M Rosenfeld; Roberto Giugliani
Journal:  J Inherit Metab Dis       Date:  2011-07-09       Impact factor: 4.982

Review 7.  International guidelines for the management and treatment of Morquio A syndrome.

Authors:  Christian J Hendriksz; Kenneth I Berger; Roberto Giugliani; Paul Harmatz; Christoph Kampmann; William G Mackenzie; Julian Raiman; Martha Solano Villarreal; Ravi Savarirayan
Journal:  Am J Med Genet A       Date:  2014-10-24       Impact factor: 2.802

8.  Heart and Cardiovascular Involvement in Patients with Mucopolysaccharidosis Type IVA (Morquio-A Syndrome).

Authors:  Christoph Kampmann; Tariq Abu-Tair; Seyfullah Gökce; Christina Lampe; Jörg Reinke; Eugen Mengel; Julia B Hennermann; Christiane M Wiethoff
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

9.  Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA.

Authors:  Hsiang-Yu Lin; Ming-Ren Chen; Shan-Miao Lin; Chung-Lieh Hung; Dau-Ming Niu; Chih-Kuang Chuang; Shuan-Pei Lin
Journal:  Orphanet J Rare Dis       Date:  2018-08-29       Impact factor: 4.123

10.  Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy.

Authors:  Hui Chen; Shaukat Khan; Betul Celik; Yasuyuki Suzuki; Yasuhiko Ago; Shunji Tomatsu
Journal:  Mol Genet Genomic Med       Date:  2021-10-08       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.